A series of lab tests also revealed that Mr. X suffered from problems like thrombocytopenia (low platelet count), hyponatremia (low sodium), hyperkalemia (higher-than-normal potassium levels), hypochloremia (low chloride), hypocalcemia (low calcium), acute kidney failure and acute liver injury. These eventually resulted in multiple-organ failure, which led to septic shock and acute respiratory failure and necessitated his transfer to the Intensive Care Unit (ICU).
Mr. X was hospitalized for a total of 22 days, eight of which he spent in the ICU. By the time the researchers submitted their report for peer-review, Mr. X was being subjected to a long-term treatment regimen involving two different antibiotics and an antifungal medication used to treat invasive fungal infections.
Despite the lack of approval from the Food and Drug Administration (FDA), psilocybin from magic mushrooms is touted as a "promising new treatment for psychiatric and behavioral disorders." These claims are not without substantial evidence.
In 2015, American researchers reported that psilocybin, given orally to a small group of volunteers, significantly reduced heavy drinking as well as the participants' dependence on alcohol. In another study conducted two years later, researchers at Johns Hopkins University School of Medicine reported similar benefits from psilocybin treatment, but this time in a small group of participants who are looking to stop smoking. The researchers said that their findings add to the growing evidence of psychedelics like psilocybin being effective treatments for addiction and substance use disorders.
In 2016, researchers at New York University Grossman School of Medicine found that a one-time, single-dose treatment of psilocybin from magic mushrooms significantly lessened the emotional distress of cancer patients. They noted that the psychological effects of the compound lasted for nearly five years, resulting in an increase in the patients' quality of life.
The researchers reported the sustained effects of psilocybin treatment on anxiety and depression in a follow-up study published last year in the Journal of Psychopharmacology. According to them, up to 80 percent of the patients in their first study showed "clinically significant antidepressant and anti-anxiety responses" three to 4.5 years after receiving that single dose of psilocybin.
The researchers said that psilocybin from shrooms could become a useful tool for enhancing the effectiveness of psychotherapy and relieving the symptoms of mental disorders – provided, of course, that this promising medicine is used correctly.
Sources include: Healthline.com 1 Healthline.com 2 LiveScience.com DailyMail.co.uk Journals.SagePub.com NCBI.NLM.NIH.gov NYULangone.orgElderly population suddenly dying off for unexplained reasons, and it’s no longer coded as covid-19
By Lance D Johnson // Share
Corporations pushing mandatory coronavirus vaccines for customers, not just employees
By Ethan Huff // Share
Good fish, bad fish: How to avoid contaminants and support sustainably farmed fish
By Virgilio Marin // Share
American cities were unprepared for financial fallout from coronavirus shutdowns
By Franz Walker // Share
Immunologist: Pfizer, Moderna vaccines could cause long-term chronic illness
By News Editors // Share
Antimicrobial resistance up in animals raised for human consumption, warns study
By Michael Alexander // Share
Health Ranger Report: Adapt 2030's David DuByne warns of a looming global FOOD CRISIS
By kevinhughes // Share
Alberta to add citizenship markers to ID cards in effort to combat voter fraud
By patricklewis // Share
Banking purge: Vietnam FREEZES 86 million accounts for noncompliance with new biometric requirements
By ramontomeydw // Share
Tesla robocars repeatedly fail at RAILROAD CROSSINGS
By ramontomeydw // Share